Stock Events

Stock Events

Oculis

$7.76

20

+$0.00+0%Thursday 06:00

Statistics

Day High

7.77

Day Low

7.76

52W High

33

52W Low

7.76

Volume

861

Avg. Volume

-

Mkt Cap

477.92M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

Nov 3Expected

Q3 2025

Q1 2026

Q2 2026

Q3 2026

-0.61

-0.47

-0.34

-0.2

Expected EPS

-0.4712608516

Actual EPS

-0.35889

Financials

-Profit Margin

Unprofitable

2023

2024

2025

0Revenue

-120.39MNet Income

Analyst Ratings

$35.83Average Price Target

The highest estimate is ⁦40.00⁩.
From 6 ratings within the last 6 months. This is not an investment recommendation.

Buy

100%

Hold

0%

Sell

0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OCS.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals competes with Oculis in the ophthalmology space, particularly in treatments for eye diseases like age-related macular degeneration.

Novartis is a major player in the development of drugs for eye conditions, directly competing with Oculis in the ophthalmic drug market.

AbbVie, through its acquisition of Allergan, has a strong presence in the eye care market, especially in treatments for conditions like dry eye, directly competing with Oculis.

REGENXBIO is involved in gene therapy for ocular diseases, offering innovative treatments that compete with Oculis's drug development efforts.

Bausch Health Companies

Bausch Health Companies, through its eye health division, competes in the same space as Oculis, particularly in treatments for eye diseases.

Roche, with its ophthalmology division, competes in developing treatments for eye diseases, including macular degeneration and diabetic retinopathy, areas Oculis is also targeting.

GlaxoSmithKline has initiatives in developing treatments for eye conditions, potentially competing with Oculis in the broader ophthalmology market.

AstraZeneca, through its acquisition of Alexion Pharmaceuticals, competes in the space of treatments for diseases including those affecting the eye, aligning as a competitor to Oculis.

About

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.

Show More

CEO

ISIN

CH1242303498

Listings

0 Comments

Share your thoughts

FAQs

What is Oculis stock price today?▼

The current price of OCS.BOATS is $7.76 USD — it has increased by +0% in the past 24 hours. Watch Oculis stock price performance more closely on the chart.

What is Oculis stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Oculis stocks are traded under the ticker OCS.BOATS.

What is Oculis market cap?▼

Today Oculis has the market capitalization of 477.92M

When is the next Oculis earnings date?▼

Oculis is going to release the next earnings report on March 22, 2027.

What were Oculis earnings last quarter?▼

OCS.BOATS earnings for the last quarter are -0.36 USD per share, whereas the estimation was -0.47 USD resulting in a +23.84% surprise. The estimated earnings for the next quarter are N/A USD per share.

What is Oculis revenue for the last year?▼

Oculis revenue for the last year amounts to 0 USD.

What is Oculis net income for the last year?▼

OCS.BOATS net income for the last year is -120.39M USD.

In which sector is Oculis located?▼

Oculis operates in the Other sector.

When did Oculis complete a stock split?▼

Oculis has not had any recent stock splits.